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Abstract
The precursors of atherogenic dyslipidemia (AD) are not well defined. Therefore, we investi-
gated 62 non-obese, non-diabetic AD and 221 normolipemic children. Anthropometric pa-
rameters, blood pressure and biochemical measures were obtained in index children, their
parents and all available siblings. The heritability (h2) of anthropometric and biochemical
traits was estimated by SOLAR. Rare and common variants in APOA1 and LPL genes were
screened by re-sequencing. Compared to normolipemic, AD children showed increased
body mass index, waist circumference, plasma glucose, insulin, ApoB, HOMA-IR, hs-CRP
and lower adiponectin (p<0.001 for all). Metabolic syndrome was present in 40% of AD
while absent in controls. All traits (except adiponectin and hs-CRP) showed a strong familial
aggregation, with plasma glucose having the highest heritability (89%). Overall, 4 LPLloss-
of-function mutations were detected (p.Asp9Asn, p.Ser45Asn, p.Asn291Ser, p.Leu365Val)
and their cumulative prevalence was higher in AD than in control children (0.073 vs. 0.026;
P=0.038). The LPLp.S447* gain-of-function mutation, resulted to be less frequent in AD
than in control children (0.064 vs. 0.126; P=0.082). No variant in the APOA1gene was
found. Our data indicate that AD is a rather common dyslipidemia in childhood; it associates
with metabolic abnormalities typical of insulin resistant state and shows a strong familial ag-
gregation. LPLvariants may contribute to the development of AD phenotype.
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Introduction
Atherogenic dyslipidemia (AD) is a highly atherogenic lipid abnormality characterized by the
combination of increased plasma concentration of triglycerides (TG), reduced high-density li-
poprotein cholesterol (HDL-C) and increased numbers of small, dense low-density lipoprotein
(sdLDL) particles [1, 2]. AD is thought to occur mainly in adulthood due to a combination of
genetic predisposition with aging and adiposity [3, 4]. Nevertheless, epidemiological observa-
tions have reported that the lipid components of AD—namely low HDL-C and high TG—may
be present since childhood [5], thus providing the rationale for searching this form of dyslipi-
demia also at younger ages. The earlier identification of AD is justified by the fact that these
lipid abnormalities in children and adolescents have been demonstrated to predict clinical
manifestation of atherosclerosis in adulthood [6].
Conditions associated to AD are central obesity and insulin resistance, which are, in turn,
strongly associated with a low-grade inflammation state and abnormalities in adipokines pro-
duction [7]. Indeed, in adults with AD higher levels of serum insulin and C reactive protein
(CRP) and lower levels of adiponectin have been also reported [8]. However, if these abnormal-
ities are early or late biochemical markers of AD phenotype is not known. The investigation of
a cohort of children could help in shedding light into this question.
Although it is well recognized that also genetic factors predispose to the development of
AD, few studies have investigated the familial aggregation of components of this lipid pheno-
type. The only indirect estimates derives from studies in metabolic syndrome (MetS) whose
components (insulin resistance, obesity, hypertension, and serum lipids) showed heritability
values ranging from 20% to 80% [9]. On the other hand, a number of candidate genes have
been linked to the lipoprotein abnormalities of AD. Among them, genes coding for lipoprotein
lipase (LPL) and apolipoprotein AI (APOAI) appear to be particularly relevant due to their piv-
otal role in regulating both TG and HDL-C levels [10–12]. Though variants in these genes may
predispose to AD, direct data in children are scanty.
Therefore, within a large investigation dedicated at dyslipidaemia in the youth, we designed
this study aimed at describing the metabolic and genetic abnormalities associated to AD in
children. As lipid abnormalities cluster within families, an additional aim of this study was to
evaluate the familial aggregation of traits associated with this disorder and to estimate the con-
tribution of rare and common genetic variants into LPL and APOA1 genes to the lipid compo-
nents of AD.
Material and Methods
Subjects’ selection and classification
For this study we have considered all children (2–18 years) referred between November 2006
and January 2012 to the paediatric Lipid Clinic of our University Hospital for suspected dyslipi-
daemia [13]. At first visit, anthropometric (body weight, waist, hip and arm circumferences) and
lipoprotein measurements were obtained in index children, their parents and all available sib-
lings. In children, weight was measured using an electronic scale (Soehnle, Murrhardt, Ger-
many), and the standing height was measured with the Harpenden Stadiometer (Holtain,
Crymych, Great Britain). Systolic and diastolic blood pressure was measured by using a random
zero sphygmomanometer (Hawksley &Sons Ltd, Lancing, UK); the mean of three measurements
was used in the analysis. Body mass index (BMI) was calculated as weight/ height2 (kg/m2).
Children showing plasma levels of TG90th and HDL-C10th age and sex-specific percen-
tiles were classified as AD [14], while those with TG<75th and HDL>10th were used as com-
parator. TG and HDL-C percentiles reported for Italian children and adult (>20 years)
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populations were used as reference values [15, 16]. Children with clinical diagnosis of domi-
nant familial hypercholesterolemia (ADH) were excluded. The criteria for diagnosing ADH
have been previously reported [13]. Additional exclusion criteria were thyroid dysfunction, di-
abetes mellitus, nephrotic syndrome and liver disease as detected by standard laboratory tests.
Subjects taking statins or other medications for lipoprotein disorder were also excluded from
the analyses.
The presence of MetS in adults was defined according to the American Heart Association
(AHA) criteria, [17]. To define MetS in children, we used the pediatric AHA definition which is
based upon the AHA adult definition but uses pediatric reference standards for blood pressure
(BP), waist circumference (WC), TGs and HDL-C [18, 19]. Thus, in our study central obesity
was defined as a WC 90th percentile for age and gender; hyperTG as triglycerides 90th per-
centile for age and gender; low HDL-C as concentrations10th percentile for age and gender;
elevated BP as systolic or diastolic BP90th percentile for age, gender, and height percentile;
and impaired fasting glucose as glucose 100 mg/dl.
Written informed consent on behalf of enrolled children was obtained from parents and all
adults gave their written consent before entering into the study. The study was approved by the
Institutional Review Board and carried out in accordance with the Helsinki Declaration.
Biochemical measurements
Blood samples were collected early in the morning after an overnight fast in EDTA-containing
tubes. Plasma concentrations of lipoprotein apoproteins, blood glucose and insulin were deter-
mined as previously described [13, 20]. Insulin resistance was estimated by HOMAIR as previ-
ously described [21]. Plasma levels of high molecular weight (HMW) adiponectin levels were
determined by ELISA kit (EZHMWA A-64K, Millipore, Missouri, U.S.A) according to manu-
facturer’s instructions. Plasma high-sensitive C-reactive protein (hs-CRP) concentrations were
analyzed by particle-enhanced turbidimetric immunoassay (C-Reactive Protein Latex High
Sensitivity—Roche Diagnostics GmbH, D-68298 Mannheim) following manifacturer’s
instructions.
Genetic analysis
Genomic DNA of 55 AD and 174 normolipemic children was obtained from peripheral blood
leukocytes by either the salting-out method [22] or the QIAamp 96 Blood DNA kit (Qiagen,
Hilden, Germany). The mutational search in LPL and APOA1 genes was performed using the
robotic systemMicrolab Starlet (Hamilton, Reno, USA) for the preparation of the reactions in
a 96-well and the ABI PRISM 3130xl (Applied Biosystems, Foster City, USA) genetic analyzer
for targeted sequencing. For the purpose of confirmation, the SNPs identified in the LPL gene
were also investigated by using the SNaPshot assay (Life Technologies, Carlsbad, USA). Details
of procedures are reported in the S1 File, S1 Table and S2 Table.
Statistical analysis
Statistical analyses were performed using the SPSS package (version 18.0; SPSS Inc., Chicago,
IL, USA) and STATA v.11. The data are expressed as either frequencies or means with standard
deviation. The variables showing a skewed distribution were reported as median (interquartile
ranges) and tested after log transformation. Student’s t-test for unpaired data or U Mann-
Whitney were used to compare continuous variables, while either Fisher’s exact test or χ2 test
was used to compare categorical variables. All comparisons were adjusted for age, sex and BMI
by using the generalized linear model (GLM). Pearson’s correlation and linear regression coef-
ficients were used to examine the relationship between variables.
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The computer package SOLAR (Sequential Oligogenic Linkage Analysis Routines, version
4.2.7) was used for heritability analyses [23]. A maximum likelihood-based variance decompo-
sition approach was used to estimate the proportion of the overall variability due to genetic
(heritability, h2) and covariates effects. The significance was assessed by means of the likelihood
ratio test, using the tdist command when residual kurtosis of the traits was>0.8, allowing a ro-
bust estimation of mean and variance of the trait. Covariates used in models included age, sex,
agesex (sex modality was 1 or 2), entering in the final model if p<0.1. The analysis was repeat-
ed after stratification for case and control families, maintaining statistical models and settings
used for the related analysis in the whole sample. Before analysis, the distribution of variables
was assessed using Shapiro-Wilk tests and variables not normally distributed were transformed
when appropriate using the statistical package SAS (version 9.1.3 for Windows, Cary, NC: SAS
Institute Inc.).
We also assessed the odds ratios for the presence of AD in the parents according to the sta-
tus of the proband using a logistic regression model, with and without adjustment for age, age
square, gender and BMI. The general estimated equation model was used to account for the
correlation among siblings within a family. In addition, the probability (odds) of a child with
AD to having a parent with the same lipid phenotype has been estimated by using logistic re-
gression analysis where age, sex and BMI were included as covariates.
All statistical tests were 2-sided and a P<0.05 was set as the statistical significance level.
Results
Identification of AD children and families
A total number of 488 Caucasian index children were originally considered for the study. Fig 1
shows the flow diagram for classification of these children. Eighty four (17.2%) were excluded
due to incomplete family data, thus leaving a study cohort of 404 children. According to the
predefined criteria, 221 children (54.7%) (89 boys and 132 girls) were classified as without AD,
32 (7.9%) with autosomal dominant hypercholesterolemia (ADH) and 89 (21.9%) with either
isolated low HDL-C or isolated high TG. Therefore, 62 (41 boys and 21 girls) were classified as
affected by AD providing a prevalence of 15.3%. Within families with AD we examined 124 pa-
rents (62 father and 62 mothers) and 43 siblings (22 brothers and 21 sisters); within families
Fig 1. Flow diagram for classification of children with atherogenic dyslipidemia.
doi:10.1371/journal.pone.0120099.g001
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with normolipemic children we examined 442 parents (221 father and 221 mothers) and 160
siblings (91 brothers and 69 sisters).
Comparison of clinical and biochemical characteristics of children with
and without AD
Table 1 shows the comparison of clinical and biochemical characteristics between children
with AD and those with normal lipids. Age and gender were not significantly different between
groups, but male sex appeared to be more frequent among AD children. Although LDL-C and
apoB, levels did not differ between groups, the LDL-C/Apo B ratio was lower in AD compared
to controls children. As reduced LDL-C/apoB has been reported to be a good predictor of
smaller LDL particles [24], this finding strongly suggests an increased prevalence of sdLDL in
the AD group. Respect to controls, BMI and waist circumference were significantly greater in
children with AD and these difference was present in both boys and girls (data not shown).
The differences in the waist circumference remained statistically significant (p = 0.038) also
when adjusted for age and sex. Plasma levels of fasting blood glucose, insulin, HOMA-IR and
hs-CRP were higher and those of HMW adiponectin were lower in children with AD compared
Table 1. Clinical characteristics and laboratory parameters of children with and without atherogenic dyslipidemia.
Variables Children with atherogenic dyslipidemia (n = 62) Children without atherogenic dyslipidemia (n = 221)
Age, (yrs) 8.2 ± 3.9 8.3 ± 3.4
Sex, Boys 41 (66%) 89 (40%)
Girls 21 (34%) 132 (60%)
BMI, (kg/m2) 21.1 ± 5.3*** 18.2 ± 3.5
Systolic BP (mmHg) 106.8 ± 10.7 108.1 ± 11.2
Diastolic BP (mmHg) 68.3 ± 10.0 70.3 ± 8.9
Waist circumference (cm) 73.0 ± 16.8*** 61.5 ± 9.6
Plasma lipids (mg/dl)
Total cholesterol 187.3 ± 37.4 198.6 ± 38.7
HDL-C 32.9 ± 5.0*** 58.8 ± 12.1
Non-HDL-C 154.4 ± 36.2*** 139.8 ± 38.3
Total triglycerides 158.9 ± 83.2*** 65.0 ± 19.2
LDL-C 122.5 ± 38.1 126.9 ± 37.4
ApoB 89.6 ± 27.5 82.4 ± 22.4
LDL-C/Apo B 1.39 ± 0.32** 1.65 ± 0.75
ApoAI 126.0 ± 25.6*** 155.3 ± 30.9
Fasting Blood Glucose (mg/dl) 77.2 ± 11.3*** 69.1 ± 11.0
Insulin (μU/ml) 11.03 ± 8.36*** 6.46 ± 4.23
HOMA-IR 2.14 ± 1.64*** 1.09 ± 0.8
hs-CRP (mg/dl) 0.08 (0.04–0.22) * 0.03 (0.00–0.12)
Adiponectin (μg/ml) 3.75 (2.45–6.04) *** 5.67 (3.88–7.41)
Metabolic Syndrome, n (%) 26 (42) *** 0
BMI, body mass index; BP, blood pressure; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; ApoB, apolipoprotein
B; ApoAI, apolipoprotein AI; hs-CRP, high sensitivity C Reactive Protein; HOMA-IR, homeostasis model assessment of IR index.
hs-CRP and adiponectin values are reported as median (interquartile range)
* p<0.05;
** p<0.01;
*** p<0.001
doi:10.1371/journal.pone.0120099.t001
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to controls. With the exception of those in adiponectin levels, all these differences remained
statistically significant after adjustment for age, waist circumference and gender. Conversely,
systolic and diastolic blood pressure did not differ significantly between groups. Twenty-six
children with AD (42%) were found to have MetS compared to none among controls.
Univariate correlations between clinical and biochemical characteristics in the whole group
of study children are reported in S3 Table. Age was a significant determinant of FBG, insulin,
HOMA-IR, BMI and waist circumference (positive) and adiponectin (negative). As expected,
BMI and waist circumference were significantly correlated with indices of insulin resistance
(positively) and TG and with adiponectin, HDL-C (negatively). Finally, hs-CRP showed a
slight, positive correlation with plasma insulin and HOMA and negative with HDL-C and
ApoAI.
Familial aggregation of AD traits
To evaluate the familial aggregation of the AD phenotype, we first compared plasma lipids and
other characteristics of parents and siblings of children with and without AD (Table 2). Parents
of AD children showed significantly higher non HDL-C, TG, LDL-C, apoB and lower HDL-C
and ApoAI levels compared to those of children without AD. Also, mean levels of fasting blood
glucose and insulin levels were higher in parents of children with AD compared to controls,
even though only the former reached a level of statistical significance. This translated in higher
HOMA index in parents of children with AD, but the difference did not reach the statistical
significance. Even though BMI was comparable between groups, the waist circumference was
significantly greater in parents of children with dyslipidemia compared with controls indicat-
ing a tendency towards increased prevalence of visceral obesity among this group. Finally,
when we compared the prevalence of MetS between groups, it was found to be almost 3 times
more frequent among parents of dyslipidemic children and this difference was highly signifi-
cant (p<0.001).
The comparison of demographic and metabolic parameters between siblings of children
with and without AD showed somewhat similar differences (Table 2). In fact, brothers and sis-
ters of affected children showed, on average, significantly higher TG and lower HDL-C and
apoA1 respect to those of normolipemic children; they also presented a tendency towards
higher indices of insulin resistance and visceral obesity, but the differences were not statistically
significant. Nonetheless, among siblings of AD children we observed a markedly increased
prevalence of MetS. To explore the extent to which AD aggregates within families further, we
estimated the heritability (h2) of the phenotypic traits in the study groups (S4 Table). All traits,
except adiponectin and hs-CRP, showed a significant genetic component, with glucose levels
having the highest heritability. Plasma levels of lipoproteins as well as apolipoprotein and their
ratios also showed strong genetic influence presenting h2 values ranging from 52% to 83%. The
groups of children with AD showed higher heritability levels for anthropometric measures and
non-HDL-C.
Genetic analysis of LPL and APOA1 genes in children with and without
AD
The analysis of APOA1 gene did not reveal any variants in both groups of children. Conversely,
the screening of LPL led to identification of 8 exonic variants, 3 of which were synonymous. Of
the 5 non-synonymous variants, 4 were missense and 1 was nonsense (Table 3). Most of them
(p.Asp9Asn, p.Asn291Ser, p.Leu365Val and p.S447) have been previously reported [25–27],
while the p.Ser45Asn variant is described here for the first time: All variants were found to be
at heterozygous state. The child carrying the p.Asp9Asn resulted to be heterozygous for the
Atherogenic Dyslipidemia in Children
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complex allele [c.-281T>G; c.106G>A] with the two variants in cis on the same allele. The seg-
regation analysis in parents assigned this complex allele to the father. The novel LPL c.215
G>A (p.Ser45Asn) variation was identified in a child showing TGs of 257 and HDL-C of 30
mg /dl. It was inherited from the father who also showed TGs 232 and HDL-C 39 mg/dl. It is
located in the amino-terminal domain of the protein that represents the site with the catalytic
activity and it is also close to a glycosylation site critical for the proper maturation of the pro-
tein. Furthermore, the in silico analysis indicated that it could be probably damaging (Poly-
Phen-2 score = 0.099; Panther, Pdeleterious = 0.221). Taking together, these results highlight that
p.Ser45Asn might have a functional effect.
When the individual frequencies of LPL variants were compared between groups, we no-
ticed that the p.N291S variant allele was significantly more common in AD than in control
children (0.045 vs. 0.006; p = 0.010) while, at the opposite, the p.S447 allele tended to be more
Table 2. Clinical characteristics and laboratory parameters of parents and siblings of children with and without atherogenic dyslipidemia.
Parents Siblings
Variables of children with atherogenic
dyslipidemia(n = 124)
of children without
atherogenic dyslipidemia
(n = 442)
of children with
atherogenic dyslipidemia
(n = 43)
of children without
atherogenic dyslipidemia
(n = 160)
Age, (yrs) 40.0 ± 6.4 40.4 ± 5.8 11.2 ± 5.8 10.2 ± 6.2
BMI, (kg/m2) 25.5 ± 3.9 24.9 ± 4.0 21.0 ± 6.2 18.7 ± 3.9
Systolic BP (mmHg) 119.8 ± 13.0 119.2 ± 13.2 102.3 ± 12.2 104.7 ± 12.3
Diastolic BP (mmHg) 75.7 ± 8.5 76.4 ± 9.3 63.4 ± 7.2 66.4 ± 8.4
Waist
circumference (cm)
93.0 ± 13.0* 88.9 ± 13.3 74.9 ± 25.1 60.3 ± 12.8
Plasma lipids (mg/dl)
Total cholesterol 211.8 ± 46.2 205.2 ± 38.7 166.9 ± 35.9 171.1 ± 38.46
HDL-C 45.0 ± 12.3*** 54.2 ± 14.5 42.4 ± 9.0‡‡‡ 55.0 ± 12.4
Non HDL-C 166.8 ± 47.6*** 150.9 ± 41.8 124.4 ± 37.1 116.1 ± 36.0
Total triglycerides 141.5 ± 88.6*** 103.7 ± 83.3 98.7 ± 63.2‡‡‡ 63.7 ± 23.5
LDL-C 139.0 ± 44.3* 130.1 ± 34.5 104.6 ± 34.1 103.3 ± 34.8
ApoB 94.4 ± 30.1** 86.7 ± 25.6 74.5 ± 24.9 73.5 ± 22.8
LDL-C/ApoB 1.51 ± 0.41 1.60 ± 0.56 1.49 ± 0.44 1.51 ± 0.67
ApoAI 147.8 ± 32.0*** 159.1 ± 34.6 133.9 ± 27.1‡‡‡ 154.1 ± 31.0
Fasting Blood
glucose (mg/dl)
83.2 ± 19.7*** 75.9 ± 13.3 77.7 ± 12.8 72.0 ± 11.4
Insulin (μU/ml) 9.68 ± 14.0 7.93 ± 4.80 8.5 ± 7.2 6.95 ± 5.35
HOMA-IR 2.54 ± 7.31 1.55 ± 1.28 1.81 ± 1.97 1.30 ± 1.07
hs-CRP (mg/dl) 0.11 (0.04–0.29) 0.09 (0.03–0.22) 0.04 (0.01–0.11) 0.05 (0.01–0.14)
Adiponectin (μg/ml) 3.44 (2.22–4.88) 3.20 (2.09–5.46) —- —-
Metabolic
Syndrome, n (%)
9 (7.2) *** 12 (2.7) 5 (11.6) ‡‡‡ —-
BMI, body mass index; BP, blood pressure; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; ApoB, apolipoprotein
B; ApoAI, apolipoprotein AI; hs-CRP, high sensitivity C Reactive Protein; HOMA-IR, homeostasis model assessment of IR index. hs-CRP and adiponectin
values are reported as median (interquartile range)
* P<0.05;
** p<0.01;
*** p<0.001 between parents
‡‡ p<0.01;
‡‡‡ p<0.001 between siblings
doi:10.1371/journal.pone.0120099.t002
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prevalent in controls than in AD children (respectively 0.126 vs. 0.064, p = 0.082). The differ-
ence in the prevalence of the other LPL variant alleles did not reach the statistical significance.
As the p.Asp9Asn, p.Asn291Ser and p.Leu365Val variants have been already demonstrated
causing loss-of-function (LOF) alleles [28] and the novel p.Ser45Asn was classified as probably
LOF, their cumulative prevalence was compared between AD and controls. We found that LPL
LOF alleles were significantly more frequent in AD than in control children (0.073 vs. 0.026,
respectively; p = 0.038) determining for AD children an almost 3 times higher risk of being car-
riers of any of them (HR = 2.95; 95% CI 1.11–7.86; p = 0.038). As the p.S447 is a gain-of-func-
tion LPL variant associated with low TG levels [29], we performed a further analysis classifying
LPL alleles in 3 classes (with the p.S447X, with all LOF and with wild type). A statistically
significant difference of their distribution between AD and control children was evidenced
(χ2 = 7.931, p = 0.019).
The comparison of lipid profile between AD children with (n = 8) and without (n = 40)
LOF alleles in the LPL demonstrated that carriers had higher TG levels compared to non-
carriers (175 ± 96 mg/dl vs. 153 ± 86 mg/dl, respectively), even though the difference was not
statistically significant probably due to the small sample size.
Discussion
In this study, we sought to evaluate the metabolic and the genetic features of paediatric AD.
Within a large cohort of children referred to a tertiary paediatric lipid clinic we found that
about 15% of them showed a lipid phenotype classifiable as AD. Although this figure cannot be
considered representative of the prevalence of AD in the general population of children, it sug-
gests that AD is a rather frequent lipid abnormality among children with dyslipidaemia, cer-
tainly more common than dominant hypercholesterolemia (7.9%) and just lower than that of
isolated hypertriglyceridemia (17.0%). We have classified AD based upon arbitrary age- and
sex- specific lipoproteins cut-off values, and some have raised concern about the reliability of
this criterion for classifying dyslipidemia in children [30]. Nevertheless, we found that AD chil-
dren showed a constellation of several metabolic abnormalities such as greater waist circumfer-
ence, higher fasting levels of plasma glucose and insulin and reduced insulin sensitivity, higher
levels of his-CRP and lower levels of adiponectin. It is also noteworthy that, compared to con-
trols, AD children showed an abnormal composition of LDL fraction as suggested by the in-
creased LDL-C/ApoB ratio. All these abnormalities have been already reported in adults
diagnosed with AD [3, 8], thus suggesting that they may represent early events in the develop-
ment of the AD trait. In addition, this finding indicates that the AD classification we used iden-
tified a group of children showing an array of generalized metabolic disorders.
It has been reported in adulthood that AD is a component of MetS [31]. This seems to be
partially true in childhood as we observed that only about 40% of AD children showed features
of MetS. This latter finding is consistent with previous observations indicating that at younger
ages (<35 years) AD is a less robust identifier of MetS, but may reflect the predisposition to an
isolated lipid disorder [32]. It must be, however, recognized that we cannot exclude that AD in
many children might foreshadows the development of MetS later in life. Moreover, AD has
been reported to be strongly related with obesity [4]. However, it must be noted that the multi-
ple metabolic abnormalities in AD children, although associated with increased waist circum-
ference, developed in the context of borderline-normal body fat and persisted even after
adjustment for measures of adiposity. One possible interpretation of our data is that the under-
lying metabolic defects in AD children reflect an insulin-resistant state that extends beyond ad-
ipose tissue. Indeed, previous investigators have postulated a condition in which a primary
condition of insulin resistance is responsible for multiple metabolic disorders, including
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dyslipidemia [33]. In addition, the observation that parents and siblings of AD children showed
predominantly abnormal lipid concentrations (and to a lesser extent visceral obesity and
insulin resistance) might also argue in favour for the co-existence of inherited defects in apoB-
containing lipoproteins metabolism in AD [34]. Indeed, it would be not surprising that an in-
sulin resistant state on a background of genetic susceptibility to metabolic abnormalities wors-
ens the expression of dyslipidemia.
An important finding of our study was that several traits associated to AD showed high de-
gree of heritability. Our results are in line with previous studies that provided evidence for a
strong association between parental metabolic disorders and abdominal obesity, high triglycer-
ides and low HDL-C in their offspring [35]. Interestingly, in our AD families, beside plasma
glucose, non-HDL-C and apoB presented the highest levels of heritability thus arguing in favor
for the existence of an inherited defect in apoB-containing lipoproteins metabolism in AD chil-
dren. It must be noted, however, that our children shared the same family environment or be-
haviour and this may emphasis the role of inheritance. Nonetheless, our data strongly argue in
favour of a significant genetic component in AD.
In this study, we have also investigated the role of LPL and APOAI as candidate genes in
predisposing children to develop AD. No sequence changes were found in APOAI, but 14.5%
of AD probands presented variants in LPL gene. AD children as a group showed 3 times higher
frequency of heterozygous LOF mutations in this gene. Moreover, the presence of LPL LOF
variants appeared to be able to affect the hypertriglyceridemic trait in affected children. Based
on these results we could postulate that abnormality in LPL, even though not causative, might
favour the development (or the worsening) of the hypertriglyceridemic trait in, at least, a subset
of AD children. It is well known that mild-to-moderate hypertriglyceridemia as well as lower
HDL-C are typically multigenic [36] and therefore other genes might be responsible of suscep-
tibility to the AD phenotype in the youth. Further resequencing studies in larger cohorts of AD
children will be necessary to shedding more light on these aspects.
Conclusions
Our study demonstrated that AD is a common dyslipidemia in childhood and this definition,
although based on rather arbitrary cut-off criteria, identified a group of children showing sever-
al underlying metabolic abnormalities, many of which appear to be under a genetic influence.
In particular, our data might suggest that the interaction between abnormalities in insulin sen-
sitivity and in the metabolism of apoB-containing lipoprotein could represent early events in
AD, which might later associate with unfavorable changes in visceral fat deposition. Moreover,
some dyslipidemic children also carry abnormalities in the LPL activity, which may also give
contribution to a hypertriglyceridemic component of AD. Overall these findings, not only con-
firm the complex nature of AD, but also have practical clinical implications. In fact, they
strongly suggest that an early detection of children with AD would allow the identification of
individuals highly prone to develop cardiometabolic risk factors in adulthood and therefore
would most benefit of earlier preventive interventions.
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Supplementary Methods 
 
Genetic Analysis 
The promoter and all 4 exons and introns of APOA1 gene and the promoter and the 10 
exons (with adjacent intronic regions) of LPL gene were analyzed. In particular, the APOA1 gene 
was divided into 4 zones for the PCR amplification (S2 Table A); each zone was subsequently 
divided into two parts for sequencing (S2 Table B). For the LPL gene, the primers flanking the 
exons were used for both PCR amplification and sequencing (S2 Table C). PCR amplifications 
were performed in a total volume of 15 µl with 50 ng of genomic DNA, 6 pmols of each primer, 
0.25 units of Go Taq hot start polymerase (Promega, USA), 175 µM of each dNTP (Fermentas, 
USA), 1.5 mM MgCl2 and 1x manufacturer’s buffer. The PCR cycle was the following: 2’ 95°C; 35 
cycles of 45’’ 94°C, 1’ 30’’ 58°C, 2’30’’ 72°C followed by 7’ 72°C. PCR products were purified by 
a common protocol based on thermosensitive alkaline phosphatase (Fermentas, USA) and 
exonuclease I (USB Corporation, USA). Sequencing reactions were performed by using the Big 
Dye Terminator Reaction Kit version 1.1 (Applied Biosystems, USA) according to the 
manufacturer’s instructions by using the genetic analyzer ABI PRISM 3130xl (Applied Biosystems, 
USA). Sequencing products were purified by Montage SEQ96 sequencing reaction cleanup kit 
(Millipore, USA) following manufacturer instructions and subsequently analyzed by the genetic 
analyzer. The sequence data were analyzed by using the software SeqScape (Applied Biosystems, 
USA) personalized for the semi-automatic recognition of sequence variations possibly found in the 
studied zones. 
The SNPs identified in the LPL gene were investigated in the general population by the 
SNaPshot assay (Life technologies, USA). Briefly, the method consisted in the amplification of 
regions containing SNPs by a multiplex PCR of 5’-UTR and exons 2, 6, 8 and 9 of LPL gene (S2 
Table C) that was subsequently purified by the exonuclease I – alkaline phosphatase method. 
Purified PCR products underwent extension reactions by using the primers reported in the S3 Table 
and in the presence of fluorescent ddNTPs. The polymerase extends the primer by only one 
nucleotide, adding a single ddNTP at its 3' end. After alkaline phosphatase purification, extension 
products were analyzed by the genetic analyzer. The data analysis was performed by a personalized 
template for Genotyper software (Applied Biosystems, USA). 
 S2 Table. Primers for PCR amplification and cycle sequencing of APOA1 and LPL genes. 
 
A) Primers for PCR amplification of APOA1. 
ANALYZED ZONE FORWARD REVERSE 
PRODUCT 
SIZE (bp) 
Ta 
(°C) 
5’ UTR - exon 3 5’-TCCTCTGCCAACACAATGG-3’ 5’GGCCAGGTCCTTCACTCG-3’ 878 58 
Exon 2 – exon 4 5-TCCTGACGGGTAGGTGTCC-3’ 5’-GCTGTCCCAGTTGTCAAGG-3’ 970 58 
Intron 3 - 3’ UTR (up) 5’-CCAGCTCTGTCTCCTTTTTAGC-3’ 5’-GCACGGAGTTGTTGAGATCC-3’ 981 58 
Exon 4 - 3’ UTR (down) 5’-GAGCTTCAAGGTCAGCTTCC-3’ 5’-TCCTGGCCTGAAGTGATACG-3’ 1151 58 
 
B) Primers for cycle sequencing of APOA1. 
ApoA1 FORWARD REVERSE 
PRODUCT 
SIZE (bp) 
Ta  
(°C) 
5’ UTR (up) – intron 1 5’-CTCCCATGGAGGGGAAGG-3’ 5’-CACAGAGCGGGAGAAGACC-3’ 421 58 
5’ UTR (down) – intron 2 (down) 5’-TGGCTGCAGACATAAATAGGC-3’  5’-CTGAGATCTGAGCCGAAAGG-3’ 465 58 
Intron 2 (up) – intron 3 (up 1) 5’-CCTAACCTAGGGAGCCAACC-3’  5’-GCCCAGCTCATCAGATATTAGG-3’  441 58 
Exon 3 – intron 3 (down) 5’-GCGGCAGAGACTATGTGTCC-3’  5’-GCAGTGGCCTAGCATTTCC-3’ 554 58 
Intron 3 (up 2) – exon 4 (down) 5’-CCTTTTTAGCTCCTCTCTGTGC-3’ 5’-AGCTCGTGCAGCTTCTGG-3’ 476 58 
Exon 4 (up) – 3’ UTR (up) 5’-AGCTCTACCGCCAGAAGG-3’ 5’-AAGCTGCTTCCCACTTTGG -3’ 459 58 
Exon 4 (down) – 3’ UTR (down) 5’-AAGCTCAACACCCAGTGAGG-3’ 5’-TAGTGGGAGGGGGATACTGG-3’ 657 58 
3’ UTR (distal) 5’-GAAGCGCTTGGAGTTTGC-3’ 5’-TGATACGCCCACCTCAGC-3’ 537 58 
 
C) Primers for PCR amplification and cycle sequencing of LPL. 
ANALYZED ZONE FORWARD REVERSE 
PRODUCT 
SIZE (bp) 
Ta 
(°C) 
5’ UTR 5’-CGTGAATCGATGTAAACCTGTG-3’ 5’-GTTTGGCGCTGAGCAAGT-3’ 377 58 
Exon 1 and adjacent intronic zones 5’-CAGTCACATAAGCAGCCTT-3’ 5’-TTCCAACTTCCTTCTTCTC-3’ 401 58 
Exon 2 and adjacent intronic zones 5’-CGTTGGAGCATCTGTTGTTCT-3’ 5’-ATGTGGGGTGCGGACCCATC-3’ 427 58 
Exon 3 and adjacent intronic zones 5’-TTGGGCTGATGTATCTATGAC-3’ 5’-GGCAGGACTATTTATTGGC-3’ 451 58 
Exon 4 and adjacent intronic zones 5’-ATTTTTGGCAGAACTGTAAGCAC-3’ 5’-AAATCTGCAGGCATTGTGTG-3’ 408 58 
Exon 5 and adjacent intronic zones 5’-TCATTTTAGAAGGAGCCAAG-3’ 5’-GTGGTCATGCTGAACATTG-3’ 569 58 
Exon 6 and adjacent intronic zones 5’-ACTCTCTTGAAGGTGGGTGG-3’ 5’-ATGGGAATTAGAAGCCTCAGAC-3’ 624 58 
Exon 7 and adjacent intronic zones 5’-TTCCATGTGTGTGCACTTCC-3’ 5’-CTTGTTTTCTAGGCATCGCTCT-3’ 350 58 
Exon 8 and adjacent intronic zones 5’-GCAGGGAGAGCTGATCTCTATAA-3’ 5’-TGTGAAGGCCCCTGAAATAC-3’ 318 58 
Exon 9 and adjacent intronic zones 5’-CCCTCTGATTCTGATGTGGC-3’ 5’-CTGGTGATGGGGTGAAGAG-3’ 363 58 
Exon 10 and intron 9 adjacent 
intronic zone - 3’ UTR 
5’-GTCTTCCATTCCTACAAACCTG-3’ 5’-TTTTACTCTGCGCTCAAACAAT-3’ 497 58 
 
  
 
S3 Table . Primers for minisequencing in the LPL gene. The underlined nucleotides are the mobility tail added. 
 
VARIATION PRIMER 
p.Asp9Asn 5’-GGAAAAGAGAAAGGAAAAAAAATTCCAGAAAGAAGAGATTTTATC-3’ 
p.Ser45Asn 5’-AAAAAACTACCTGTCATTTCAATCACA-3’ 
p.Asn291Ser 5’-AATCTGGGCTATGAGATCA-3’ 
p.Leu365Val 5’-AAAGGAAAACACAAATAAGACCTACTCCTTC-3’ 
p.Ser447* 5’-AGAAAAAAGGGAAAAATGACAAGTCTCTGAATAAGAAGT-3’ 
 
 
 
 
 S4 Table. Correlations between variables in the whole group of study children (n=283)   
______________________________________________________________________________________________________________________________ 
Variables Age TC HDL-C TG LDL-C FBG Insulin hs-CRP Apo B Apo A1 Adiponectin HOMA-IR BMI 
TC 0.025             
HDL-C -0.006 0.224**            
TG 0.070 0.008 -0.532**           
LDL-C 0.009 0.944** -0.013 -0.096          
FBG 0.221** 0.010 -0.224** 0.300** 0.008         
Insulin 0.486** -0.101 -0.312** 0.356** -0.089 0.246**        
hs-CRP -0.009 -0.082 -0.154* 0.007 -0.021 -0.055 0.160*       
ApoB 0.020 0.579** -0.144* -0.014 0.671** 0.046 0.016 0.040      
Apo A1 0.070 0.130* 0.589** -0.267** -0.024 -0.096 -0.166* -0.138* -0.042     
Adiponectin -0.381** 0.141 0.224* -0.142 0.093 -0.061 -0.353** -0.113 0.023 0.054    
HOMA-IR 0.483** -0.066 -0.332** 0.420** -0.063 0.424** 0.970** 0.151* 0.043 -0.146* -0.343**   
BMI 0.410** -0.006 -0.275** 0.323** 0.010 0.340** 0.575** 0.043 0.076 -0.163* -0.413** 0.587**  
Waist circ. 0.617** -0.060 -0.373** 0.467** -0.044 0.190 0.712** 0.151 0.066 -0.153 -0.319* 0.649** 0.841** 
_____________________________________________________________________________________________________________________________ 
TC, total cholesterol; HDL-C, high density lipoprotein cholesterol; TG, triglycerides; LDL-C, low density lipoprotein cholesterol; FBG, fasting blood glucose; 
hs-CRP, high sensitivity C Reactive Protein; HOMA-IR, HOmeostasis Model Assessment of IR index; BMI, body mass index 
 
 *p< 0.05; **p< 0.01 
 
 
 1 
S5 Table. Heritability (h2) values and effect of covariates (age, sex and their interaction) in the whole sample and stratified for case/control 
families. 
 
 
Overall (1052 subjects, 283 
families) 
AD families (229subjects, 62 
families) 
Control families (823subjects, 
221families) 
 
h2 (SE) 
(%) 
P 
values 
Covariates 
(%) 
h2 (SE) 
(%) 
P values 
Covariates 
(%) 
h2 (SE)  (%) P values 
Covariates 
(%) 
BMI 44.1 (5.7) 9.E-15 53.7 52.1 (11.4) 6.E-06 33.5 40.8 (6.6) 2.E-10 57.9 
Waist circumference 29.7 (9.9) 1.E-03 67.6 45.6 (17.8) 6.E-03 55.0 17.7 (11.9) 0.06 80.1 
Hip circumference 42.2 (12.4) 4.E-04 0.2 78.9 (18.0) 1.E-04 60.6 22.4 (15.9) 0.08 0.0 
PAD 15.8 (8.2) 2.E-02 24.4 Ne -  22.5 (9.1) 5.E-03 24.4 
PAS 18.1 (8.8) 2.E-02 30.1 5.3 (21.2) 0.40 28.5 20.4 (9.6) 1.E-02 30.9 
Glucose 88.9 (3.7) 4.E-59 17.1 90.4 (7.8) 8.E-15 13.9 86.2 (4.4) 1.E-42 18.5 
Insulin 22.1 (6.4) 1.E-04 2.6 26.9 (14.3) 3.E-02 0.2 18.9 (7.2) 3.E-03 6.4 
HOMA 32.2 (6.8) 5.E-07 3.0 30.9 (15.8) 2.E-02 0.0 26.8 (7.7) 2.E-04 7.2 
Total cholesterol 45.7 (6.1) 7.E-14 15.0 71.2 (10.8) 2.E-08 20.5 37.5 (7.1) 3.E-08 14.3 
HDL 63.5 (4.6) 1.E-35 13.5 32.8 (13.5) 5.E-03 21.5 48.3 (6.1) 5.E-15 18.8 
Non-HDL 55.2 (5.5) 3.E-21 12.7 68.6 (11.5) 4.E-07 8.7 48.7 (6.3) 2.E-14 14.9 
Non-HDL/HDL ratio 66.2 (4.9) 2.E-31 22.3 47.4 (14.8) 1.E-03 10.7 55.0 (6.2) 1.E-16 29.4 
LDL 58.9 (5.4) 6.E-25 8.4 74.6 (9.5) 2.E-10 8.8 52.5 (6.3) 2.E-16 8.8 
Tryglicerides 58.4 (5.6) 3.E-22 27.3 28.7 (13.7) 1.E-02 5.9 45.0 (6.7) 4.E-11 28.2 
ApoAI 67.0 (4.7) 2.E-35 8.1 51.4 (10.7) 2.E-06 12.5 66.4 (5.7) 3.E-25 8.3 
ApoB 74.8 (4.8) 6.E-36 13.5 81.3 (9.9) 8.E-10 11.2 73.0 (5.4) 9.E-29 13.6 
ApoAI/HDL ratio 72.2 (5.1) 3.E-33 13.5 57.8 (12.9) 2.E-05 12.2 64.7 (6.4) 1.E-19 19.3 
ApoB/non-HDL ratio 83.0 (4.1) 1.E-51 0.0 77.3 (9.6) 4.E-10 0.2 84.5 (4.5) 1.E-42 0.7 
ApoB/Apo-aI ratio 75.8 (4.8) 6.E-38 11.6 60.8 (11.5) 1.E-06 6.4 76.9 (5.3) 2.E-31 12.9 
Adiponectin 16.8 (13.2) 0.10 15.5 7.6 (17.3) 0.33 7.2 43.8 (18.7) 2.E-02 22.0 
CRP 23.4 (7.4) 5.E-04 8.4 20.7 (14.4) 0.07 0.0 25.2 (8.6) 1.E-03 14.8 
MetSyn 65.5 (16.9) 8.E-05 1.82* Ne -  49.6 (147.2) 0.40 20.5* 
*Kullback-Leibler R-squared for categorical variables 
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